Rifampicin/Isoniazid

DEA Class; Rx

Common Brand Names; Rifamate (DSC)

• Antitubercular Agents

Hypersensitivity to isoniazid, rifamycins

Acute liver disease, severe hepatic damage, acute gout

Rifampin is contraindicated in patients receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity

Rifampin is contraindicated with many drugs that are substrates of CYP, particularly CYP3A4

Rifampin coadministration in patients receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir may substantially decrease plasma concentrations which may result in loss of antiviral efficacy for HIV infection and/or development of viral resistance

—

History of diabetes mellitus (may make diabetes management more difficult)

Rifampin is not recommended for intermittent therapy; caution patient against intentional or accidental interruption of daily dosage regimen since rare renal hypersensitivity reactions have been reported when therapy was resumed in such cases

Rifampin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal hormones, thyroid hormones, and vitamin D

No adequate and well-controlled studies have been performed in pregnant women; has been shown to be teratogenic in rodents

Because of potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother

Rifampin/isoniazid

capsule

• 300mg/150mg